# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.statnews.com/pharmalot/2024/05/14/amgen-lumakras-durbin/
Mizuho analyst Salim Syed maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $223 to $235.
Trading in U.S. index futures suggests stocks may be off to a lackluster start again on Thursday.
- Milken Conference